Latest Insider Transactions at Glycomimetics Inc (GLYC)
This section provides a real-time view of insider transactions for Glycomimetics Inc (GLYC). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of GLYCOMIMETICS INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of GLYCOMIMETICS INC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 11
2022
|
Timothy R Pearson |
BUY
Open market or private purchase
|
Direct |
19,400
+44.04%
|
$19,400
$1.29 P/Share
|
|
Mar 09
2022
|
Brian M. Hahn SVP Finance, CFO |
SELL
Open market or private sale
|
Direct |
2,917
-7.34%
|
$2,917
$1.09 P/Share
|
|
Mar 09
2022
|
Armand Girard SVP, Chief Business Officer |
SELL
Open market or private sale
|
Direct |
2,339
-9.36%
|
$2,339
$1.09 P/Share
|
|
Mar 09
2022
|
John L. Magnani SVP of Research, CSO |
SELL
Open market or private sale
|
Direct |
3,227
-1.0%
|
$3,227
$1.09 P/Share
|
|
Nov 16
2021
|
Patricia S Andrews |
BUY
Open market or private purchase
|
Direct |
40,000
+46.92%
|
$80,000
$2.05 P/Share
|
|
May 18
2021
|
Timothy R Pearson |
BUY
Grant, award, or other acquisition
|
Direct |
5,250
+50.0%
|
-
|
|
May 18
2021
|
Scott Koenig |
BUY
Grant, award, or other acquisition
|
Direct |
5,250
+50.0%
|
-
|
|
May 18
2021
|
Mark Alan Goldberg |
BUY
Grant, award, or other acquisition
|
Direct |
5,250
+50.0%
|
-
|
|
May 18
2021
|
Patricia S Andrews |
BUY
Grant, award, or other acquisition
|
Direct |
5,250
+50.0%
|
-
|
|
May 18
2021
|
Scott Thomas Jackson |
BUY
Grant, award, or other acquisition
|
Direct |
5,250
+50.0%
|
-
|
|
May 18
2021
|
Daniel M Junius |
BUY
Grant, award, or other acquisition
|
Direct |
5,250
+10.82%
|
-
|
|
Jan 20
2021
|
Rachel K. King |
BUY
Grant, award, or other acquisition
|
Direct |
96,250
+17.55%
|
-
|
|
Jan 20
2021
|
John L. Magnani SVP of Research, CSO |
BUY
Grant, award, or other acquisition
|
Direct |
34,500
+9.62%
|
-
|
|
Jan 20
2021
|
Helen M. Thackray SVP Clinical Development, CMO |
BUY
Grant, award, or other acquisition
|
Direct |
34,500
+15.85%
|
-
|
|
Jan 20
2021
|
Brian M. Hahn SVP Finance, CFO |
BUY
Grant, award, or other acquisition
|
Direct |
34,500
+46.46%
|
-
|
|
Jan 20
2021
|
Armand Girard SVP, Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+50.0%
|
-
|
|
Dec 28
2020
|
Rachel K. King |
SELL
Open market or private sale
|
Direct |
84,176
-19.12%
|
$252,528
$3.91 P/Share
|
|
Dec 28
2020
|
Rachel K. King |
BUY
Exercise of conversion of derivative security
|
Direct |
130,821
+22.91%
|
$130,821
$1.12 P/Share
|
|
Dec 16
2020
|
Brian M. Hahn SVP Finance, CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
5,260
+50.0%
|
$5,260
$1.12 P/Share
|
|
Nov 04
2020
|
Bvf Partners L P > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
1,266,737
+11.98%
|
$2,533,474
$2.6 P/Share
|
|
Oct 30
2020
|
Bvf Partners L P > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
932,612
+7.81%
|
$1,865,224
$2.75 P/Share
|
|
Sep 05
2019
|
Bvf Partners L P > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
1,668,746
+19.01%
|
$5,006,238
$3.18 P/Share
|